Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 55Terminated 39Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 84Specimen Handling 79Carboplatin 74Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 55Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35Rituximab 34olaparib 33Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Pemetrexed 27Doxorubicin 27Docetaxel 27Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Has results × Interleukin-2 × Clear all
NCT01416831 2026-04-24

SBRT/IL-2

Providence Health & Services

Phase 2 Active not recruiting
44 enrolled 12 charts
Dermatologic

Melanoma

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

University of California, Davis

Phase 1/2 Active not recruiting
18 enrolled 13 charts
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡